Immuneering Corp(IMRX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $2.3M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
IMRX Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Immuneering Corp (IMRX), a Healthcare sector company. IMRX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $2.3m in revenue. Based on the latest XBRL financial filings (Q1 2026), Immuneering Corp reports net income of $-13.5M, free cash flow of $-18.5M. Top institutional holders of IMRX by reported 13-F value include FMR, Sanofi, MARSHALL WACE, LLP, based on the most recent SEC filings. IMRX trades on the Nasdaq exchange and files with the SEC under CIK 1790340. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IMRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Immuneering Corp directly from SEC EDGAR.
Net Income
Q1 2026
$-13.5M
Free Cash Flow
Q1 2026
$-18.5M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
Net Income
+8.2% YoYOperating Income
+7.3% YoYEPS (Diluted)
+37.7% YoYTotal Assets
+340.1% YoYOp. Cash Flow
+17.6% YoY| Metric | FY 2025 | FY 2024 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Revenue | — | — | $317.0K -84.8% | $2.1M -10.0% | $2.3M |
| Net Income | $-56.0M +8.2% | $-61.0M -20.8% | $-50.5M -50.6% | $-33.5M -96.8% | $-17.0M |
| Operating Income | $-59.4M +7.3% | $-64.1M -23.8% | $-51.7M -52.7% | $-33.9M -98.4% | $-17.1M |
| EPS (Diluted) | $-1.27 +37.7% | $-2.04 -6.8% | $-1.91 +22.4% | $-2.46 +28.5% | $-3.44 |
| Total Assets | $232.0M +340.1% | $52.7M -56.9% | $122.4M -26.6% | $166.7M +333.9% | $38.4M |
| Operating Cash Flow | $-45.3M +17.6% | $-55.0M -24.7% | $-44.1M -42.9% | $-30.9M -111.0% | $-14.6M |
AI Insight: IMRX Ratio Trends
Immuneering's return metrics collapsed through mid-2025, then stabilized at deeply negative levels; profitability remains elusive.
• ROE deteriorated from -84.9% in Q2 2024 to -199.5% in Q2 2025, then recovered sharply to -26.1% in Q1 2026.
• ROA and ROIC show similar V-shaped pattern: ROA bottomed at -85.2% in Q3 2024, recovered to -25.1% in Q1 2026.
⚠ Company remains unprofitable across all periods; no margin data available indicates ongoing pre-commercialization or development stage.
⚠ Latest quarter (Q1 2026) ROE/ROA/ROIC stabilized ~25–30% negative but remain far from acceptable returns; inflection timing uncertain.
Get alerted when IMRX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Immuneering Corp including:
Top Institutional Holders of IMRX
FMR LLC
$51.1M9,697,938 shSanofi
$14.3M2,708,559 shMARSHALL WACE, LLP
$10.5M1,996,585 shBlackRock, Inc.
$7.9M1,507,258 shMILLENNIUM MANAGEMENT LLC
$5.8M1,102,712 shGEODE CAPITAL MANAGEMENT, LLC
$3.4M637,944 shOccam Crest Management LP
$2.9M545,098 shCITADEL ADVISORS LLC
$2.4M447,278 shConnor, Clark & Lunn Investment Management Ltd.
$2.1M400,363 shSummit Financial, LLC
$2.0M376,749 sh
| Fund | Value | Shares |
|---|---|---|
| FMR LLC | $51.1M | 9,697,938 |
| Sanofi | $14.3M | 2,708,559 |
| MARSHALL WACE, LLP | $10.5M | 1,996,585 |
| BlackRock, Inc. | $7.9M | 1,507,258 |
| MILLENNIUM MANAGEMENT LLC | $5.8M | 1,102,712 |
| GEODE CAPITAL MANAGEMENT, LLC | $3.4M | 637,944 |
| Occam Crest Management LP | $2.9M | 545,098 |
| CITADEL ADVISORS LLC | $2.4M | 447,278 |
| Connor, Clark & Lunn Investment Management Ltd. | $2.1M | 400,363 |
| Summit Financial, LLC | $2.0M | 376,749 |
More Healthcare Companies
View all Healthcare →Put IMRX on your watchlist
Track score changes the day Immuneering Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is IMRX a good stock to buy?
13F Pro's AI-powered analysis of Immuneering Corp (IMRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IMRX are available on the IMRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own IMRX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IMRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Immuneering Corp's investment landscape.